百乐眠胶囊联合喹硫平治疗轻中度抑郁症的临床研究

目的 探讨百乐眠胶囊联合富马酸喹硫平片治疗轻中度抑郁症的临床疗效.方法 选取2019年6月—2020年6月天津港口医院收治的100例轻中度抑郁症患者,按照随机数字表法将全部患者分为对照组和治疗组,每组各50例.对照组口服富马酸喹硫平片,2次/d,总剂量第1天50 mg,第2天100 mg,第3天200 mg,第4天30...

Clinical study on Bailemian Capsules combined with quetiapine in treatment of mild to moderate depression

Objective To investigate the clinical efficacy of Bailemian Capsules combined with Quetiapine Fumarate Tablets in treatment of mild to moderate depression. Methods Patients (100 cases) with mild to moderate depression in Tianjin Port Hospital from June 2019 to June 2020 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were po administered with Quetiapine Fumarate Tablets, twice daily, the total dose was 50 mg on the first day, 100 mg on the second day, 200 mg on the third day, and 300 mg on the fourth day according to the patient''s tolerance and clinical response, and the dose was maintained at 150-750 mg/d. Patients in the treatment group were po administered with Bailemian Capsules on the basis of the control group, 4 grains/time, twice daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and the HAMD-24 score, the SDS score, the WHOQOL-BREF score, and the levels of BDNF, IL-18, and 5-HT in two groups were compared. Results After treatment, the total effective rate was 94.00% in the treatment group and 78.00% in the control group, and there was significant difference between the two groups (P < 0.05). After treatment, the HAMD-24 score and SDS score of two groups were significantly reduced (P < 0.05). After treatment, the HAMD-24 score and SDS score of the treatment group were lower than those of the control group (P <0.05). After treatment, physical scores, psychological scores, social relationship scores, and environmental scores in two groups were significantly increased (P < 0.05). After treatment, physical scores, psychological scores, social relationship scores, and environmental scores in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the levels of BDNF and 5-HT in two groups were significantly increased, but the level of IL-18 in two groups were significantly decreased (P < 0.05). The levels of BDNF and 5-HT in the treatment group were higher than those in the control group, while the IL-18 level in the treatment group was lower than that in the control group (P < 0.05). Conclusion Bailemian Capsules combined with Quetiapine Fumarate Tablets is effective in treatment of mild to moderate depression, and can relieve the clinical symptoms, regulate the secretion of BDNF, 5-HT, and IL-18, improve the quality of life, with good safety.